BioCryst Pharmaceuticals, Inc. stock performance trend indicates that the stock price has rallied 26.61% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 100.68% . Looking at the past 52 week period, the stock price is up at 236.5% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of BioCryst Pharmaceuticals, Inc. has a positive value of 93.25 compared to overall market.Based on the Stock Research the Relative Strength Index signal is in over bought territory with a range of 71.99.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has tumbled 0.34% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 34.91% in the last four weeks. The stocks have underperformed the S&P 500 by 0.57% during the past week but BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) it has outperformed the index in 4 weeks by 33.37%.
For the current week, the company shares have a recommendation consensus of Buy. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) : On Friday heightened volatility was witnessed in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) which led to swings in the share price. The stock opened for trading at $8.69 and hit $8.92 on the upside , eventually ending the session at $8.85, with a gain of 0.57% or 0.05 points. The heightened volatility saw the trading volume jump to 1,719,390 shares. The 52-week high of the share price is $9.15 and the company has a market cap of $655 million. The 52-week low of the share price is at $2.36 .
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.BioCryst Pharmaceuticals was Initiated by Ladenburg Thalmann on Feb 16, 2017 to Buy, Price Target of the shares are set at $11.
Company has reported several Insider transactions to the SEC, on Mar 14, 2017, Thomas R Ii Staab (Senior Vice President and CFO) sold 3,250 shares at 9.06 per share price.On Sep 16, 2016, Alane P Barnes (VP, General Counsel & Corp Sec) sold 8,357 shares at 4.27 per share price.On Aug 29, 2016, Yarlagadda S Babu (Senior VP – Drug Discovery) sold 30,000 shares at 4.06 per share price.
BioCryst Pharmaceuticals Last issued its quarterly earnings results on Feb 27, 2017. The company reported $-0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.18. Analyst had a consensus of $-0.24. The company had revenue of $9.00 million for the quarter, compared to analysts expectations of $4.60 million. The companys revenue was up 95.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.25 EPS.
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.